All supplements

Supplement evidence

049 / 575Experimental longevity

Resveratrol

View my plan

The short answer

Trials examine glucose, vascular, and inflammatory markers with inconsistent results.

Evidence and scope
Mixed evidence

This status does not grade the ingredient for every goal, outcome, or person.

Important limitation
Animal mechanisms and biomarker changes have not established human lifespan extension.
Before deciding
GI effects and interactions with anticoagulants and drug-metabolizing enzymes are concerns.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective
Glucose-related research150–1,000 mg/day across trials; no established clinical dose

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat-soluble / lipid-based

Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.

How it is commonly taken

Take with food; formulation changes exposure.

Do not combine casually

Anticoagulants, estrogen-sensitive conditions, surgery, CYP interactions, pregnancy, and cancer therapy require review.

Dose and use source

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

5research papers in this ledger
4unique primary studies represented
255unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2024
Evidence contextPMID 38255828

Resveratrol for the Management of Human Health: How Far Have We Come?

The review found no conclusive clinical evidence supporting recommendation in a healthcare setting and called for larger, higher-quality trials.

Study design and methods
Design
Systematic review of clinical trials across indications
Population
Multiple human populations
Intervention
Purified resveratrol at defined doses
Outcome
Multiple clinical and biomarker outcomes
Open research record
2021
Supports a specific usePMID 32900519

Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women

The study reported small improvements in cognition and several secondary vascular or metabolic measures in this population.

Study design and methods
Design
Randomized, double-blind, placebo-controlled crossover trial
Population
Postmenopausal women aged 45–85
Intervention
Trans-resveratrol 150 mg/day versus placebo
Outcome
Cognition and cerebrovascular function
Open research record
2018
Does not support the tested claimPMID 29548848 · NCT02621554

Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults

The trial did not show significant improvement in its main verbal-memory outcome.

Study design and methods
Design
Randomized, double-blind, placebo-controlled trial
Population
Adults aged 60–79
Intervention
Resveratrol 200 mg/day versus placebo
Outcome
Verbal memory and brain imaging
Open research record
2014
Supports a specific usePMID 24899709

Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults

The small trial reported improved memory performance and related surrogate measures.

Study design and methods
Design
Randomized, double-blind, placebo-controlled trial
Population
Healthy overweight older adults
Intervention
Resveratrol 200 mg/day versus placebo
Outcome
Memory and hippocampal connectivity
Open research record
2013
Does not support the tested claimPMID 23193181

High-dose resveratrol supplementation in obese men

No meaningful metabolic benefit was demonstrated over four weeks.

Study design and methods
Design
Randomized, double-blind, placebo-controlled trial
Population
Obese but otherwise healthy men
Intervention
High-dose resveratrol versus placebo
Outcome
Insulin sensitivity, metabolism, and body composition
Open research record
Unscreened discovery appendix—not evidence530 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.
  1. Conventional and nonconventional therapies for pesticide-induced cardiotoxicity: A systematic review.de Almeida DL, da Costa SJG, Silva VC et al. · 2026 · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · PMID 42508715Open on PubMed
  2. Autophagy potential of polyphenols in breast carcinoma: A systematic review.Golchin A, Teymori Nobari S, Maleki M et al. · 2026 · Pathology, research and practice · PMID 42475944Open on PubMed
  3. Protocol for a randomized, controlled trial of a bioactive dietary polyphenol preparation to promote resilience in healthy individuals.Marchidan MM, Rizk MM, Karpman E et al. · 2026 · Contemporary clinical trials · PMID 42320787Open on PubMed
  4. Resveratrol as an Adjunct Therapy in Periodontal Disease: A Systematic Review and Meta-Analysis.Su SY, Tzeng IS, Huang TH et al. · 2026 · Nutrients · PMID 42451212Open on PubMed
  5. Contribution of Resveratrol on Periodontal Disease Control and Treatment: A Systematic Review.Bandiaky ON, Bechina C, Vanden Berghe M et al. · 2026 · Oral health & preventive dentistry · PMID 42384081Open on PubMed
  6. Resveratrol supplementation and assisted reproduction outcomes: A systematic review and meta-analysis.Lemos MJ, Oliveira JA, Queiroz LF et al. · 2026 · European journal of obstetrics, gynecology, and reproductive biology · PMID 42150354Open on PubMed
  7. Effects of turmeric and curcumin in patients on dialysis or using immunosuppressive agents: a systematic review.Rajabian F, Khajavi Rad A, Ghorban Sabbagh M et al. · 2026 · Naunyn-Schmiedeberg's archives of pharmacology · PMID 42047771Open on PubMed
  8. Polyphenols increase circulating lipids but improve LDL particle quality and reduce LDL oxidation in postmenopausal women: metabotype- and age-dependent effects in a randomised, placebo-controlled crossover trial.García-Nicolás M, Jarrín-Orozco MP, Romo-Vaquero M et al. · 2026 · European journal of nutrition · PMID 42371155Open on PubMed
  9. The Gut-Bone Axis and Skeletal Health: Regulatory Mechanisms and Therapeutic Applications of Plant-Derived Bioactive Compounds.Zhang T, Li Y, Pei J et al. · 2026 · Biomolecules · PMID 42352378Open on PubMed
  10. The effects of resveratrol on glycemic indices and lipid profile in patients with type 2 diabetes: an umbrella review and meta-analysis.Ghalichi F, Molani-Gol R, Tejareh F et al. · 2026 · Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · PMID 42268476Open on PubMed
  11. The neuroprotective and therapeutic potential of resveratrol for traumatic spinal cord injuries: a systematic review.Moselmani M, Khayat D, Ajami S et al. · 2026 · BMC neurology · PMID 42265649Open on PubMed
  12. The proBNPage reduction (PBAR) trial-results of a randomized, double blind, placebo-controlled, pilot study to fine tune an NT-proBNP-based method to assess the effect of anti-aging treatments.Muscari A, Forti P, Magalotti D et al. · 2026 · GeroScience · PMID 40922000Open on PubMed

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.

Educational information only—not medical advice. Product quality, dose, medicines, pregnancy, and kidney or liver disease can materially change safety.